Categories
Health

Why the Walmart, Walgreens and CVS well being clinic experiment is stalling

Bobbi Radford showed up at the CVS MinuteClinic in Batavia, Ohio, last Thanksgiving because she was experiencing pain in her arm.

“I waited an hour and then I was told to go to the [emergency room].,” Radford said. After telling the staff member her medical history of congestive heart failure, she was instructed to go to the emergency room. But Radford says after she did that, the emergency room discovered she had tennis elbow.

“It was a waste of time and I still had to go to my GP,” Radford said.

Despite their initial promise of convenience and accessibility, in-store clinics have not proven to be the golden goose many retailers initially envisioned. That's why Walmart recently announced it would close its 51 full-service stores. Another symptom of the weakening market is Walgreens, which has announced the closure of 160 VillageMD stores (Walgreens owns a 53% stake in VillageMD, which also operates freestanding clinics). CVS' MinuteClinic, the largest in-store clinic with over 1,100 locations, has announced dozens of clinic closures this year in Southern California and New England.

Not all patient experiences are negative. Karla Lemon of Conway, South Carolina, says she uses CVS' MinuteClinic for vaccinations or sinus infections. “I've had pretty good experiences with them,” Lemon said.

Yet the business experience in the retail health clinic space has been largely disappointing. That's not a big surprise to Timothy Hoff, a professor of health systems management at Northeastern University. Hoff has researched retail health clinics and the type of primary care they provide, and says margins can be slim to nonexistent and that many other challenges have hindered their success. What was not long ago considered the “2.0” version of primary care is now taking a back seat as in-store clinics close.

“1.0 was the rise of urgent care centers. These were places 20 or 30 years ago that gave people alternatives to primary care doctors,” Hoff said. But about 15 years ago, Hoff said, those spaces began moving into high-traffic stores like grocery stores and department stores, with health care trying to reach people where they were. But this brought challenges that many retailers and even some providers were unfamiliar with.

“Some of these organizations have grown that part of their business too quickly and haven't realized the cost model of maintaining these clinics,” Hoff said. Insurance reimbursements for these clinics are low, but costs have increased significantly. “I just don't think it's worth it for a lot of places to have a lot of these clinics. Some of these large organizations are downsizing and pulling out,” Hoff added.

Retail clinics rely on selling large quantities. “If you can't pump through a lot of patients, it doesn't work,” Hoff said. The staffing situation was also a problem. “Ultimately, it was more expensive to operate than expected, and combined with the lack of staff, it just didn't work.”

There's also the issue of cross-selling. Many retail chains use clinics as loss-leaders to steer customers toward other products and services they sell: They lure customers into the clinic in the hopes that they'll buy other things. But that model hasn't worked. If someone is sick enough to seek treatment, they probably won't be in the mood to buy a pint of ice cream or socks while they're away. Likewise, “people who come in to shop aren't necessarily going to hop into the clinic,” Hoff said.

A Retail Reality Check for MinuteClinic

Colleen Sanders, a Washington, D.C., nurse who now works in health education, worked at MinuteClinic for two years. She pointed to margin and staffing issues she experienced.

“Healthcare is a business in the United States. Even though we look at the huge billions of dollars that are being generated, that doesn't mean there are going to be huge profit margins. I think retailers have realized they're not going to make millions and millions of dollars,” Sanders said. “The profit margins are slim.”

Labor costs further squeezed already slim margins. When Sanders worked at MinuteClinic, she had to do everything herself, from checking in patients to billing and cleaning the clinic at the end of the day. The support staff was inadequately trained at best, she said. “That was the model to make sure they could do it so they didn't have to hire additional staff. But with that much work, you need support staff to give the professionals time to focus on patient care, because that's where you can bill insurance and generate revenue.”

The 15 minutes she was allowed to treat a patient was often simply not enough for the complex conditions patients were suffering from. For some patients, treatment simply wasn't fast enough: Sanders recalled a 7-year-old she was treating commenting that the treatment took more than a minute. Ultimately, the “want it now” culture of Americans is not a good fit for medicine, and that is precisely what the clinic closures indicate. “The pace at which we want to achieve health care is not congruent with actually providing the level of service we should be providing, coupled with the cost of support staff,” Sanders said. “If we wanted to curb retail health care, we would use registered nurses instead of physician assistants, but that would be too expensive.”

CVS declined to comment directly on the closures, but a spokesperson described the latest strategy as a combination of healthcare options – a mix of virtual, in-store and at-home services – that offers a “more convenient experience.”

Walmart and the problem of quantity and price

In 2019, Walmart announced a bold initiative to open 4,000 health centers in its stores by 2029. But those plans ended with the recent closure of the 51 centers it opened.

“Primary health care is a low-margin business,” said Arielle Trzcinski, a senior healthcare analyst at research firm Forrester. “Compared to what you see in traditional retail, healthcare is a fundamentally different business,” Trzcinski said, citing the challenges of dealing with insurance companies and the administrative burdens that come with that.

Retailers cannot recoup their money by offering primary care as a loss leader in the same way as other healthcare organizations.

“Primary care is a feeder for patients who need more urgent services like surgery or specialists. Hospitals make money on the back end and Walmart or Walgreens didn't have that,” Trzcinski said. CVS is doing better because its merger with health insurer Aetna now allows it to sell other services, including mental health.

“Walmart ultimately thought they were solving an important problem,” Trzcinski said, but added that Walmart never really put all of its marketing muscle into the effort or built relationships with other employers to create a path to the clinic. “They wanted to make health care more affordable and more convenient for their customers. But to do that, you need volume. … To make it work, you need volume or a different pricing structure, and Walmart ended up having neither one nor the other properly calibrated.”

A missed opportunity for rural America

According to Sanders, the limitations of the business model have even undermined one of the great promises of the retail clinic concept: providing health care to rural areas.

“Walmart tried to go into rural areas where there were few vendors and fill a community need. I think that's a great idea because everyone knows where the local Walmart is. But it's a real challenge to get vendors to go and work in rural areas. The quality of life and the things that people can do in a small town are not as attractive as in urban centers, so they pay vendors a premium to work there,” Sanders said, and that's another factor that cuts into revenue.

Retail will continue to experiment with this model.

Dollar General, for example, has tried a workaround by offering mobile clinics that visit some of its rural locations and provide a range of minor medical services.

Another way for Amazon to make money is with the recent launch of One Medical, which charges existing Prime members a subscription fee of nine dollars per month.

“You get your money whether you use the service or not, and it's a good price if you need the treatment,” said Virgil Brantz, CEO of Washington-based fintech healthcare platform MacroHealth. The treatment is virtual, but you can also just show up if you're near a One Medical facility. Unlike most models that make money when patients come, “Amazon makes more money when you don't show up. So this retail model is a little different,” Brantz said.

In-store health centers can be profitable and viable, and retailers are experimenting with phased approaches tailored to the local market. Walgreens recently announced the opening of a handful of in-store health centers in Connecticut to be operated by Hartford HealthCare. The clinics will be called “Hartford HealthCare at Walgreens.” Patients can go beyond the typical services of smaller clinics and take advantage of Hartford's larger network of specialists and treatment options.

And in Phoenix, a Walgreens branch near the Arizona State University campus has a “Be Well Health Clinic” that specializes exclusively in sexual health issues.

“The common thread is that this is a locally based partnership with a local provider with the shared goal of providing convenience and access,” a Walgreens spokesperson said.

Meanwhile, Atlanta-based Little Clinics, owned by Kroger, is shifting its service offerings to focus on geriatric care.

Walmart and Kroger did not respond to requests for comment.

This is all part of what Hoff calls “Healthcare 3.0”: a progressive disruption and evolution of primary care based on market and customer needs, including the involvement of physician offices. New models will emerge, and not every model will work.

“Every few years, there are a number of outsiders who try to make changes in health care, for better or for worse,” Brantz said. Inevitably, they “run into the wall of reality, which shows how complex health care can be.”

Clarification: Walgreens owned a 63% stake in VillageMD, but last year it reduced its stake to 53% in a restructuring. The story has been updated to reflect this.

Categories
Entertainment

Brittany Cartwright hits again at feedback about her son Cruz's well-being

Brittany Cartwright shuts down her haters.

After separation from estranged husband Jax Taylor In February, the Valley star shared an emotional message criticizing people for speculating about her son's well-being Cruz3, during the separation.

“You can join in the drama of my life, I don't care, but keep my innocent son's name out of it!!!” Brittany wrote in an Instagram story on May 28. “Don't act like you know he watched 30 minutes of a show that was taped last summer.”

And the 35-year-old stuck to her stance, explaining that she did not want “strangers to pretend to know what was going on in his life.”

“I do everything I can for him, so how dare some of you!?” Brittany continued. “He is a perfect and innocent child.”

She noted that she doesn't care what people say about her and Jax, adding, “Enough is enough!!!!!!”

Categories
Technology

Berlin-based startup Cloover receives $114 million to assist customers change to photo voltaic power

Climate and fintech startup Cloover has announced a $114 million (€105 million) funding round to further accelerate Europe’s transition to renewable energy.

The Berlin-based startup was founded in 2022 by Peder Broms, Jodok Betschart, Tony Kirmo and Valentin Gönczy. Their vision is to drive the energy transition, with a particular focus on solar power for private households.

Clover has built a platform that connects installers, prosumers, manufacturers, energy suppliers and investors.

Providers can offer their services as a subscription, and consumers can rent renewable technologies – especially solar modules, but also other applications such as batteries — instead of committing to the acquisition costs in advance or seeking external financing.

The <3 of EU technology

The latest gossip from the EU tech scene, a story from our wise old founder Boris and questionable AI art. Free in your inbox every week. Sign up now!

The company leverages its proprietary data on consumer energy savings and combines it with multiple financing options on the platform, allowing the startup to extend financing options to households that previously had no access to it.

In addition, Cloover’s platform enables vendors to secure working capital for their operations.

The startup specifically targets small and medium-sized installers, who it says account for over 85% of all solar installations in Europe.

“Our software gives this target group the same sophisticated digital tools that the major players have long had, enabling them to compete on equal terms and accelerate the adoption of sustainable energy,” said Valentin Gönczy, co-founder and CPO of Cloover.

Cloover has several partners across Europe, including Zonduurzaam in the Netherlands and Solarkraft in Sweden.

With the fresh capital, the startup wants to advance the development of its installer software as well as its sales, payment and financing offerings.

Lowercarbon Capital led the financing round with participation from 9900 Capital and QED. The latest financing follows a €7 million investment last October.

The European solar market grew by 40% in 2023. Cloover wants to meet this demand and connect one billion people to renewable energy.

One of the themes of this year's TNW Conference is “Venture: Show Me The Money.” If you want to dig deeper into what it takes to fund your startup, discover the next company to support, or just want to experience the event (and say hi to our editorial team), we have something special for our loyal readers. Use code TNWXMEDIA at checkout to get 30% off your Business ID, Investor Passport or starter packages (Bootstrap and Enlarge).

Categories
Science

Downplaying gentle stress to hype up international warming misinforms the general public about coral bleaching – what’s the purpose?

By Jim Steele

Why did such major coral bleaching occur during the El Niño event?

During an El Niño, warm water stored in the Pacific warm basin of the Coral Triangle sloshes eastward, lowering water temperatures in the western Pacific and raising temperatures in the eastern Pacific, as shown by the temperature anomalies in Figure A.

It also shifts convection centers eastward from the more westerly positions during La Niña and neutral conditions. The resulting changes in air circulation cause downward airflow typical of heat domes and clearer skies over the western Pacific, Atlantic, and Caribbean. This leads to more intense solar radiation and coral light stress in these regions.

Because of the biochemistry that controls photosynthesis, high light stress leads to increased production of dangerous oxidants (also known as ROS: Reactive Oxygen Species). Dangerous oxidants damage living tissue, which is why all organisms naturally produce and absorb antioxidants. So when coral's symbiotic algae produce too many ROS and overwhelm a coral's natural antioxidant systems, the coral sheds its symbiotic algae to prevent further damage, and that leads to coral bleaching.

As peer-reviewed science explains,

“The most likely explanation for the most common form of mass coral bleaching is the production of reactive oxygen species associated with photosystem I of photosynthesis (and to some extent photosystem II): namely superoxide (O2-), hydrogen peroxide (H2O2) and singlet oxygen.”

See “A review: The role of reactive oxygen species in mass coral bleaching Szabó (2020)

Alarmist scientists with a global warming agenda (e.g. Hughes or Hoegh-Guldberg) always tell the clickbait media the same story, namely that global warming is the main cause of coral bleaching. However, increased solar radiation causes both severe light stress and heat stress, and heat stress can reduce the effectiveness of coral antioxidant protection. So both excessive heat and light can increase the accumulation of ROS.

What is the main cause? Unfortunately, studies have rarely satisfactorily separated the two factors. But the studies that have done so suggest that light stress is the main factor. Read for example: Antioxidant responses to heat and light stress differ by habitat in a common reef coral Hawkins (2015). For the species Stylophora pistillata they state:

“Overall, changes in the symbionts' enzymatic antioxidant activity were primarily caused by irradiance rather than temperature, and responses were similar across depth groups. Taken together, our results suggest that in the absence of light stress, warming from 1°C/day to 4°C above ambient temperature is not sufficient to induce significant oxidative stress.”

Thus, regions of reduced cloud cover during El Niño events correlate with the so-called 'global' bleaching events that occurred in 1998, 2010, 2014–2017, and now 2023–24. Accordingly, large El Niño events occurred in the eastern Pacific in 1997–98, 2014–16, and 2023–24, and a Modoki El Niño in 2009–2010. As can be seen from the white circles in Figure B, the bleaching mortality rate during the 2023–24 El Niño is associated with regions in the Caribbean, Gulf of Mexico, and western Pacific, where El Niño caused atmospheric subsidence and reduced cloud cover, increasing light stress.

The alarmists who seek power cannot control solar radiation, but they want to control the population's energy consumption. So they unscientifically blame global warming for coral bleaching as proof that rising CO2 levels are killing corals! Alarmists deny science!

Like this:

How Is loading…

Categories
Health

What it’s best to learn about human circumstances and vaccines

Cows stand at a feedlot in Quemado, Texas on June 14, 2023.

Brandon Bell |

US health authorities are monitoring bird flu in humans and making preparations to combat it, but at the same time stress that the risk to the general population remains low.

A strain of bird flu called H5N1 has been confirmed in dairy cows in nine U.S. states and two people, while a global outbreak is occurring in poultry and other animals. The latest case was This was announced on Wednesday in the case of a worker on a dairy farm in Michigan. A child in Australia was also recently infected with bird flu, the country announced on Tuesday.

Since 2020, the H5N1 virus has been spreading among an increasing number of animal species around the world, but its discovery in U.S. livestock earlier this year was an unexpected turn for health authorities. In rare cases, bird flu viruses can jump to humans, causing mild to severe symptoms that may require hospitalization.

There is currently no evidence that H5N1 is transmitted from person to person. The US Centers for Disease Control and Prevention has also stated that the risk of infection is higher among farm workers than among the general population.

Still, the U.S. government and state and local health authorities are monitoring new and spreading infections in humans and animals. Federal agencies in the U.S. and elsewhere have also been monitoring the H5N1 virus for years to monitor its evolution.

The U.S. government has long stockpiled vaccines and medicines in case of a possible bird flu pandemic. Last week, it began preparing nearly five million doses of vaccine that is expected to work well against H5N1, among other measures, the Department of Health confirmed to CNBC.

Some infectious disease experts told CNBC the U.S. government appears to be fundamentally prepared if bird flu spreads further and more easily crosses over to humans, especially compared to how well prepared the country was for the Covid pandemic. The experts said most of the necessary tools are already in place, but the government needs to make sure it uses them effectively when needed.

“There are already a lot of elements in place that help us understand that we can respond to this more quickly,” said Dr. Andrew Pekosz, a professor at the Johns Hopkins Bloomberg School of Public Health. “But as always, it's about the efficiency of our responses, right? We know what we can do. We just need to be able to do it effectively.”

The recent infection in a Michigan dairy worker is no surprise, according to experts and the government. The CDC said Wednesday that similar cases in humans could be identified because high levels of the virus have been found in the raw milk of infected cows.

Millions of vaccine doses

The U.S. government currently has two vaccine virus candidates that it believes are well-matched to H5N1. These are weakened versions of a virus that trigger a protective immune response in the body and can be used to make vaccines.

Both candidates are already available to manufacturers, according to the CDC. The government began manufacturing 4.8 million doses of these vaccines last week in case of need, the HHS confirmed.

Pekosz called those doses a “first line of defense in case there is actual human-to-human transmission.” He said that number is enough to contain an early-stage outbreak, which could include vaccinating farmworkers and some health care workers.

However, he stressed that far more resources would be needed for the more than 300 million people in the United States if the virus spreads on a large scale among humans.

“Five million won’t get us very far. This is just a quick start,” said Pekosz.

According to NBC News, U.S. health officials said on May 1 that the government could deliver more than 100 million doses of bird flu vaccine for humans within three to four months if needed.

Specifically, two doses of the vaccine are required, meaning 100 million doses are only enough for 50 million people. This means that the US would need about 600 million doses if it wanted to vaccinate the entire population.

The government is facing a difficult decision about how many vaccines to prepare, especially since production takes several months.

“Either too little or too much. For example, if you prepare too much food, a lot of it will be wasted,” said Dr. Peter Chin-Hong, an infectious disease physician at UCSF Health. “That's really the big problem now with a vaccine when there's a potential threat. It's the high cost and the high risks.”

Chin-Hong said post-Covid misinformation and vaccine skepticism made that decision all the more difficult, but he believes you can “never invest too much in preparing for potential pandemics,” especially at a time when climate change, population growth and other factors are making them increasingly likely.

The Food and Drug Administration would have to approve bird flu vaccines before they go on the market, but Pekosz said that would likely be a “quick process” because the FDA is used to approving seasonal flu vaccines that are made using the same manufacturing process as bird flu shots.

Possible mRNA vaccinations

U.S. health officials are also in talks with mRNA vaccine makers about possible bird flu shots for humans. Few details have been released about those negotiations, but the Health Department said a final announcement is expected soon.

Unlike traditional flu shots, mRNA works by teaching cells to produce a harmless part of a virus that triggers an immune response against certain diseases. It is the same technology that both Pfizer And Modern used in their Covid vaccines.

Chin-Hong said mRNA vaccines could be updated more quickly to match the strains of bird flu currently circulating. But he said these vaccines come with their own challenges, such as needing to be stored at extremely cold temperatures.

In a statement to CNBC, Moderna confirmed that it is in negotiations with the government about its experimental pandemic flu vaccine, mRNA-1018, which targets the exact strain of the virus responsible for the outbreak in dairy cows.

The biotechnology company began testing this vaccine last summer as part of an early- to mid-stage study.

Pfizer declined to confirm negotiations with the government. The company said it was continuing to monitor the spread of H5N1 and was testing its mRNA-based vaccine candidates against pandemic influenza in an early trial.

Virus monitoring and treatments

CDC and its partners, including state and local health departments, use several surveillance systems to monitor seasonal flu and other illnesses. They also have special methods for detecting and monitoring new flu viruses.

Seasonal flu spreads primarily among humans, with predictable peaks throughout the year, while avian flu spreads primarily among wild birds and other animals.

The CDC said it is watching for the H5N1 virus spreading to or among people in areas where the virus has been detected in animals or people. So far, the agency has found “no evidence of unusual flu activity in people,” including H5N1, according to an update on the agency's website last week.

The CDC also conducts ongoing analyses of seasonal and emerging flu viruses to identify genetic changes that might make the viruses more severe in humans, spread more easily between people, or be less sensitive to vaccines and medications.

Although there is widespread testing at the federal, state and local levels, it is far more difficult for the average person to get tested for bird flu and receive a diagnosis than it is for Covid, Chin-Hong said. That is “the big obstacle, especially in the populations that are being affected now,” he said.

Chin-Hong is referring to farmworkers, many of whom are immigrants, who may have difficulty navigating the U.S. health care system due to language barriers and lack of access to health care.

If people do contract the virus, there are some FDA-approved antiviral drugs for seasonal flu that can also be used for bird flu. These include Tamiflu, a prescription oral medication that should be taken within 48 hours of symptoms onset.

A worker on a Texas dairy farm who was diagnosed with bird flu in March was treated with an antiviral drug and recovered, a CDC report said.

However, Pekosz said that antiviral drugs available in national stockpiles would likely not be enough for the vast majority of the population, so manufacturers may be asked to increase their supplies.

According to Francesca Torriani, an infectious disease specialist at UC San Diego Health, the average person can protect themselves from bird flu by avoiding contact with live or dead animals that may be infected, such as livestock or chickens.

People who have to come into contact with these animals should wear appropriate masks and eye protection and wash their hands afterwards.

Torriani added that pasteurized milk and cheese are probably safer to consume than raw milk products because the pasteurization process kills harmful bacteria.

Don't miss these exclusive reports from CNBC PRO

Categories
Sport

Pacers are annoyed by shut losses, however see worth in playoff run

  • Jamal Collier, ESPNMay 28, 2024, 2:33 a.m. ET

INDIANAPOLIS – Indiana Pacers center Myles Turner was still full of conflicting emotions after the Eastern Conference finals.

On one hand, Turner – the team's longest-tenured player, drafted by Indiana in 2015 – called this season an incredible journey. After missing the playoffs the previous three seasons, the Pacers won their first playoff series in more than a decade and reached the Conference Finals for the first time since 2014.

But the fact that the Pacers led in the fourth quarter in three of their four losses to the Boston Celtics still stung as players left the arena Monday night after losing Game 4 105-102 to clinch Boston's series victory.

“It's still fresh for all of us,” Turner said. “It's very frustrating to have all these games in hand and then let it slip away.”

Editor's Favorites

2 relatives

Indiana played the last two games without star guard Tyrese Haliburton, who was out with a left thigh injury, but the Pacers didn't use his absence as an excuse, especially because the Pacers knew they had a chance to win multiple games in the series.

According to research by ESPN Stats & Information, the Pacers had at least a 90% chance of winning in the fourth quarter of Games 1, 3 and 4. They lost all three games.

In Game 1, they led 117-114 with the ball and 9 seconds left. In Game 3, they were ahead 109-101 at home with 2:25 left. And in Game 4 on Monday, they were up 98-90 with 5:40 left, but failed to score in the final 3:30 minutes.

“For a young team like us, this experience in the playoffs is unmatched,” said Pacers guard Andrew Nembhard, who scored the most points on his team with 24 points. “A lot of things were our first time. A lot of little things that we maybe wanted to do better, and we learned how these games go and what it feels like to be in a series.”

Yes, the Pacers had a roster full of players making their first playoff appearances, like Nembhard, Haliburton and Aaron Nesmith. But veteran Pacers forward Pascal Siakam, who won the championship with the Toronto Raptors in 2019, stressed that it's not a given that Indiana will get that chance again.

“I can tell you we're going to learn from this and it's going to happen, but it's not guaranteed,” Siakam said. “I know how hard it is to get to this point. It's unfortunate. You want to give the other team credit for taking advantage of every mistake we made. They did a good job.”

“But for us it was tough, one heartbreaking loss after another. Yes, that encourages you and you hope to put in the work necessary to keep getting better. Because we have to get a lot better if we want to keep up with these teams. And you have to understand that no matter how well we played, we didn't get there.”

Siakam, who will be a free agent this summer after coming to Indiana via a trade during the season, declined to comment on his future but stressed several times that he was grateful to have felt supported during his time in Indiana.

“It's been a blessing,” Siakam said. “I'm really grateful for everything. Considering where I come from, it means a lot to me.”

The Pacers established themselves as one of the league's breakout teams by advancing to the In-Season Tournament Finals in early December. They posted 47 wins and secured the 6th seed in the Eastern Conference, while Haliburton was named an All-Star starter and named to the All-NBA third team.

“It's still fresh for all of us,” Myles Turner, the Pacers' longest-tenured player, said after Game 4. “It's very frustrating to have all these games in hand and then let it go.” Trevor Ruszkowski/USA TODAY Sports

Indiana picked up two series wins during this playoff round by surprising a higher seed. The Pacers beat the Milwaukee Bucks in the first round and the New York Knicks in the conference semifinals.

The Pacers were also lucky with injuries and had to play against Milwaukee without Giannis Antetokounmpo, while the Knicks' Jalen Brunson, OG Anunoby and Josh Hart were out due to injuries in the second round.

The Pacers then had to deal with injuries of their own in the conference finals, as Haliburton suffered a left thigh injury in Game 2 that sidelined him for the rest of the series. In his first 15 playoff games, Haliburton averaged 18.7 points and 8.2 assists.

“Ty never got rattled, man,” Turner said. “Whatever teams threw at him, he found a way.”

Ultimately, Indiana couldn't get over the loss of its star player enough, but as the Pacers players grappled with their emotions about the end of the season, they repeatedly emphasized how far they had come in such a short time.

“We grew as teammates all year, we grew as a whole culture,” Pacers forward Obi Toppin said. “It felt like everyone gave everything they could every day to support this organization. Obviously, the season didn't end the way we wanted it to, but there was a lot of good that came out of this season. And we don't want to overlook that.”

“It's been a big year for the Pacers and the entire organization, so we don't want to overlook that.”

Categories
Science

Mars InSight has one closing activity: to be swallowed by the mud on the Pink Planet

Normally, you don't want dust getting into your spacecraft. That was certainly true of the InSight mission to Mars until it crashed. But now it's acting as a dust collector and scientists on the Mars Reconnaissance Orbiter (MRO) couldn't be happier.

The High Resolution Imaging Science Experiment (HiRISE) aboard MRO monitors and photographs the surface. In particular, it has photographed landing sites on Mars to track dust accumulation on the surface. The idea is to see how quickly the landers and their close surroundings become covered. But it's not just focusing on landing sites. It's also checking out places like impact craters to track surface changes in and around those regions. As you can see in the latest image above, taken on April 1, 2024, the InSIGHT lander is becoming increasingly difficult to spot due to ever-increasing dust accumulations.

Monitoring surface changes on Mars

HiRISE has been keeping an eye on the InSIGHT lander since it first touched down on Mars. Early images show the hardware in quite a bit of detail immediately after landing. But over time, as the Martian winds take their toll, it's obvious that the spacecraft is becoming covered in dust. This is also true of other spacecraft that HiRISE photographs from time to time.

The best image from the InSight lander, taken by HiRISE in 2019. HiRISE scientists were looking for dust devil tracks and other surface changes caused by dust. Image credit: NASA/JPL-Caltech/UArizona

Why should we care about dust? Although we know a great deal about Mars, there is still much to be explored. Dust deposition by wind is part of the so-called aeolian processes that change the appearance of the Martian surface. They are named after the Greek wind god Aeolus. Dust storms are certainly visible on Mars from Earth, but we can't really “see” their deposits without getting close to (or being on) the planet. Other activities, such as dust devils, also spread dust around the planet. All of this activity creates wind streaks, sand and dust deposits, and covers spacecraft on the surface.

Studying aeolian processes is one of the key science topics of the HiRISE instrument. There is not much water to alter the surface, nor is there volcanic activity on Mars to scar the landscape. Impact craters do tear the surface, but they are not common, leaving aeolian activity a major factor in changes to the Martian surface. Image after image reveals dunes, ripples, wind streaks, dust devil tracks, and other features created by the winds. The HiRISE imaging project provides a “wide-angle view” of aeolian effects on the Red Planet and how its various surface units change over time.

InSight's future on Mars

The InSight lander performed almost flawlessly during its four years of operation on Mars. Although one of its instruments, the “mole,” had some trouble digging, the mission was quite successful overall. The seismograph monitored marsquakes throughout the mission, which provides details about the interior of Mars. It also distinguished between quakes from inside Mars and those caused by impacts. The spacecraft's other instruments studied the remnants of the weak magnetic field and monitored Martian weather.

The InSight lander not only measured seismic movements on Mars, but also studied the atmosphere and listened to its winds. Image courtesy: NASA/JPL.

As InSight's solar panels became covered with increasing dust, mission scientists had to shut down many of its systems. The seismometer was the last to be shut down. The spacecraft was officially considered “dead” after mission controllers did not hear from it after two attempts to communicate. The last time anyone heard from it was on December 15, 2022.

Although its instruments are silent and its solar panels are dead, the spacecraft is passively and rapidly accumulating dust, giving scientists the opportunity to understand how the surface is changing due to aeolian activity.

For more informations

Revisit InSight
Aeolian Topics for HiRISE
Winds of Mars
InSight mission completed

Like this:

How Is loading…

Categories
Entertainment

Rachel Lindsay responds to Bryan Abasolo's request for authorized charges

Rachel Lindsay has reportedly responded to her estranged husband's request to cover his legal fees during the divorce.

RELATED: Husband of Rachel Lindsay, first black 'Bachelorette,' files for divorce after 4 years of marriage, demands spousal support

Rachel Lindsay responds to her estranged husband Bryan Abasolo's plea

According to RadarOnline, Lindsay is asking a judge to deny Bryan Abasolo's request to cover his legal fees in the ongoing divorce and instead require Abasolo to make the payments himself.

In addition, she has stated that she hoped to settle their divorce “quietly and without court intervention.” In addition, Lindsay stated that she still hopes to achieve this “through a global settlement, which will take place shortly.”

“In the meantime, Bryan continues to live in Rachel's house, for which Rachel is responsible for 90% of all costs,” her lawyer said. Laura Waters, is said to have been claimed.

According to the outlet, Lindsay has not yet responded to Abasolo's general request for spousal support. The outlet adds that she “did not check the boxes to deny his request for support.” However, she also did not “check the box to award him support.” Instead, she reportedly listed “Is set” to their recently submitted response.

A brief summary of the couple's divorce proceedings so far

As The Shade Room previously reported, Abasolo filed for divorce from Lindsay in January after four years of marriage. At the time, Abasolo gave the separation date as December 31, 2023.

At that time, it became known that Abasolo wanted to obtain spousal support from Lindsay.

He also spoke about his decision on social media.

A few days after the divorce news surfaced, Lindsay broke her silence on the matter, according to The Shade Room.

“It's obviously a difficult time – if you've read the headlines… you're probably wondering why I should even be working,” she said on her podcast Higher Learning. “But to be honest, I need to take my mind off myself and the best way to do that is to do something I love…”

Lindsay stated at the time that she would comment further publicly on the matter at a later date.

Earlier this month, according to The Shade Room, Abasolo demanded emergency child support from Lindsay. At the time, Abasolo demanded that Lindsay cover at least $75,000 of his legal fees. In addition, Abasolo claimed that his monthly income was low compared to Lindsay's, so he would also need her help moving out of their shared home in Los Angeles, California.

“Rachel and I live together in our family residence, but neither of us wishes to continue living together. Our current living situation is very uncomfortable and strained. I would like to move out of our family residence as soon as possible, but maintaining our standard of living is not financially feasible at this time,” he reportedly explained.

RELATED: Rachel Lindsay's estranged husband reportedly demands urgent spousal support during their divorce
Categories
Technology

EU regulation to advertise clear applied sciences comes into drive in June

The EU's Net-Zero Industry Act (NZIA) is set to come into force at the end of June following its final adoption today. The key regulation aims to ensure that domestic cleantech companies can meet at least 40% of the bloc's needs by 2030.

“Demand is growing in Europe and worldwide and we are now in a position to meet a larger share of this demand with European supplies,” EU Commissioner Ursula von der Leyen said in a statement.

The Union hopes that by increasing its domestic production capacity, it can reduce its dependence on third countries to develop net-zero technologies. This includes the bloc's reliance on China to import solar panels.

NZIA’s main actions

The law focuses on the development of a range of technologies that are strategically important for the EU's decarbonisation plans, including solar energy, batteries and energy storage, wind energy and renewable hydrogen.

In addition, the creation of more favourable processes, such as regulatory real-world laboratories and faster approval processes, is intended to mobilise investments.

In addition, the NZIA will focus on providing vocational training and introducing net zero ‘valleys’ with the aim of creating clusters that can boost manufacturing activity.

Global race for green technologies

The NZIA is part of the EU's Green Deal industrial plan, which aims to make Europe the “home of clean technology”. But competition for leadership in green technologies is heating up and the bloc is at risk of falling behind international rivals.

One of them is the USA. In 2022, the Biden administration introduced the Inflation Reduction Act (IRA) – a $369 billion subsidy package for cleantech products made in North America.

Since its announcement, EU leaders have expressed concern that the law has the potential to discriminate against companies based in the Union or lure them across the Atlantic.

Another competitor is China. The Asian country dominates the production of solar technology and has a market share of 80 percent. The EU is also investigating China for unfair competition practices in the production and supply of wind turbines.

It remains to be seen whether the NZIA, together with the other Green Deal initiatives, can attract the €1.5 trillion in annual investment that Brussels considers essential to meet the EU's latest climate target: a 90% reduction in CO2 emissions by 2040.

Categories
Health

Digital well being firms are launching packages round GLP-1s

Patent protection for Wegovy — Novo Nordisk’s blockbuster weight loss drug, which contains the second generation GLP-1 active ingredient and is at least twice as effective — is expected to expire by the decade’s end.

Michael Siluk | UCG | Getty Images

For Gray Beard, a kindergarten teacher in Charlotte, North Carolina, losing weight had become a grueling task. She’d tried five different programs in her life and never found lasting results.

Her luck started to change last year, when she saw a promotion on Instagram for the Ro Body Program, a new offering from online health startup Ro. The ad said eligible patients could get prescribed GLP-1s, the buzzy class of obesity treatments that’s turned into a booming business in recent years.

Beard, 47, had previously sought a GLP-1 prescription, but her doctor “wouldn’t even try” to get it approved, assuming her insurance company would reject coverage of the costly medication, she said. GLP-1s cost roughly $1,000 per month before insurance and other rebates. 

Customers of Ro’s Body Program could get prescribed a GLP-1, such as Novo Nordisk ‘s weight loss drug Wegovy or diabetes treatment Ozempic, and meet monthly with a doctor. They also get access to an educational curriculum, 24/7 messaging, one-on-one coaching with nurses and assistance with navigating insurance complexities. 

Beard was 210 pounds when she first started the program early last year. She’s since lost 40 pounds and serves as an ambassador for Ro. She pays $30 per month for the GLP-1 treatment, after insurance coverage, along with a $145 monthly fee for the program. And she has no plans to leave.

“I’m fine if I have to stay on it forever,” Beard told CNBC.

Ro, founded as Roman in 2017, is part of a growing crop of digital health companies aiming to capitalize on the soaring demand for GLP-1s by building programs and services for users on top of the medications. The opportunity could be massive. Goldman Sachs analysts expect 15 million U.S. adults to be on anti-obesity drugs by 2030, and predict the industry could reach $100 billion in annual revenue by that time.

In addition to Wegovy and Ozempic, the GLP-1 class includes Eli Lilly’s highly popular weight loss drug Zepbound and diabetes treatment Mounjaro. GLP-1s mimic a hormone produced in the gut to suppress a person’s appetite and regulate blood sugar.

Like Ro, other non-drugmakers, including Calibrate, Sesame, Omada Health, Noom, Hims & Hers and even telehealth industry veterans Teladoc Health and WeightWatchers, have rolled out offerings geared toward patients on GLP-1s, or have expanded their services to include the popular medications.

Meanwhile, investors are cheering them on.

Shares of Ro competitor Hims & Hers popped 28% on May 20 after the company said it’s now offering compounded GLP-1 injections in addition to its oral medication kits. CEO Andrew Dudum told CNBC the company is confident customers will be able to access a consistent supply of the injections. 

Supply shortages are one of the big hurdles for companies in the market, as spiking demand has made it difficult for many patients to access the treatments. There’s also been a rise of counterfeit products, according to the World Health Organization, which said in January that the combination of shortages and the “increased circulation of falsified versions” is particularly problematic for patients with Type 2 diabetes who count on the medication for disease management.

That’s not slowing down industry executives like Ro founder Zachariah Reitano.

Ro didn’t start out as a company focused on weight loss. Reitano launched it to sell treatments online for erectile dysfunction before moving on to hair loss and other pathologies.

In 2020, Ro switched to obesity management and, after Wegovy was approved by the Food and Drug Adminstration the following year, Reitano said patient inquiries started pouring in by the “tens of thousands.”

Now, Ro is shoveling marketing dollars into its GLP-1 program — from digital ads, TV commercials and posters lining subway stations, to influencer campaigns featuring patients such as Beard. 

Reitano told CNBC that GLP-1s are like a “jetpack for positive behavior change.” Patients tend to exercise more, eat healthier and see around a 30% reduction in calorie intake, he said.

“Once you get a little bit of momentum, once you lose a little bit of weight, you’re sleeping better, you have more energy, you can go to the gym, you can eat better and then that’s that positive flywheel,” Reitano said.

Ro has raised around $1 billion in funding to date, according to PitchBook. The company was valued at about $7 billion as of early 2022, though that was before a steep drop in tech stocks and collapse in the initial public offering market forced many startups to dramatically lower their valuations.

WeightWatchers joins the market

WeightWatchers has been in business for over 60 years and is the name in the U.S. perhaps most synonymous with weight loss programs.

In December, the company entered the GLP-1 market, with a behavioral-support program that’s available through its general membership subscription, starting at $23 per month. Members can participate whether they get a GLP-1 prescription through their primary care physician or through the new WeightWatchers Clinic, introduced alongside the behavioral program.

Because GLP-1s suppress appetites, WeightWatchers quickly learned that it needed an entirely new program for people taking the meds, said Gary Foster, the company’s chief scientific officer.

“They don’t need help with what to do for dessert or how to deal with the bread on the table at a restaurant,” Foster said in an interview. “That’s like 50-60% of what we would do for people without meds.” 

Clinic members who participate in the GLP-1 program have to pay an additional fee — starting at $99 a month — for exclusive access to registered dieticians, fitness professionals and care team coordinators. 

WeightWatchers said in its first-quarter results earlier this month that 87,000 people had subscribed to the clinic, although not all of them are taking GLP-1s. The company expects to have between 140,000 and 160,000 clinic subscribers by year-end, the report said. 

It hasn’t been enough to change WeightWatchers’ trajectory. The stock has plummeted 83% this year on concerns about the company’s debt load, its core weight loss business and Oprah Winfrey’s announced departure from the board in February.

With respect to GLP-1s and their impact on weight loss, “the landscape is quite exciting,” Foster said. “I think we should all celebrate and really be delighted by the fact that there are more tools in the toolbox to help people trying to manage their weight.” 

Kim Gradwell with an Ozempic injection needle at her home in Dudley, North Tyneside, Britain, October 31, 2023. 

Lee Smith | Reuters

Jennifer VanGilder, a 51-year-old economics professor at Ursinus College in Collegeville, Pennsylvania, said she’d tried countless methods to lose weight, from strict diets to services like the defunct Jenny Craig. She was considering bariatric surgery before she came across a program from digital health startup Calibrate.   

Calibrate, founded in 2019, was one of the first companies to treat obesity by combining GLP-1s with one-on-one coaching. The program costs $199 a month, which doesn’t include the medication, and requires an initial three-month-long commitment.

VanGilder signed up nearly four years ago and started taking the weekly diabetes injection Ozempic specifically for weight loss. She later switched to Wegovy. 

VanGilder said GLP-1s aren’t a miracle drug, but by taking them and putting in the work, she said she lost around 100 pounds of her 242-pound weight. The big difference between Calibrate and prior weight loss efforts, VanGilder said, is that she doesn’t feel like she’s dieting.

“That’s why I’ve been able to stay on it for as long as I have,” VanGilder said.

Calibrate is one of the only companies to regularly release reports detailing the results of its weight loss program. The company’s 2024 report examined data from roughly 16,000 members who completed at least one year of the program as of October, along with a smaller group of patients who continued for longer. 

Average weight loss among patients was 16.2% at 12 months in the program, 17.3% at 18 months and 17.9% at 24 months, according to the report. 

“Our data of proven outcomes shows that we can deliver faster, better results than some of the leading GLP-1 clinical trials,” said Dr. Kristin Baier, Calibrate’s vice president of clinical development, in an interview.

But Calibrate has hit some major speed bumps in the past couple years.

After raising $100 million in venture funding during the peak of the tech market in 2021, the combination of supply shortages, insurance challenges and the broader market swoon forced the startup to lay off hundreds of employees between 2022 and 2023. The company was acquired in October at a discount by private equity firm Madryn Asset Management.

Calibrate CEO Rob MacNaughton said the sector was “ill equipped” to manage the “dramatic demand that led to, at some point, severely, severely constrained supply” of GLP-1s last year. 

Under new ownership, the company continues to promote its GLP-1 service, which its said is important because the drugs themselves aren’t sufficient.

“GLP-1 medications, while they are safe and effective, they are a tool,” said Baier. “They are not the entire treatment.”

Options for patients

Ro’s Reitano said shortages of Wegovy and other GLP-1s last year prompted his company to temporarily pause advertising. Ro also dolled out refunds and credits to patients in its program who weren’t able to pick up their medication within 30 days of receiving a prescription, he said. 

Reitano said Ro has built up “both technical tools and operations” to help patients navigate supply issues. That includes transferring prescriptions to different pharmacies based on their GLP-1 supply and proximity to a patient. From July to August, the company made 50,000 phone calls to pharmacies across the U.S. to coordinate those transfers, Reitano said. 

Ro has also expanded its medication offerings, adding Zepbound following its U.S. approval in November. 

“We added that to our formulary, and that’s really when we started advertising again because we had confidence that we’d be able to get patients an option,” Reitano said. 

Insurance problems persist, though.

Some employers have dropped weight loss drugs from their plans due to the costs associated with covering the treatments for thousands of patients. The federal Medicare program by law can’t cover weight loss drugs unless the prescription is for another approved health benefit, such as diabetes or cardiovascular health. 

Eli Lilly and Novo Nordisk offer commercial savings card programs that aim to expand access to their GLP-1s. Eli Lilly allows people with insurance coverage for Zepbound to pay as low as $25 for a monthly prescription. And users who can’t get insurance coverage, may be able to get the drug for as low as $550 a month.

The high costs and difficult access led Hims & Hers to initially stay out of the GLP-1 market even after launching its new weight loss program in December

Dr. Craig Primack, senior vice president of weight management at Hims, said the company decided to offer treatment regimens based on drugs that had been studied and prescribed for decades.  

“We’re going to have people, for one reason or another, who either don’t want an injection at this point, or are just looking for a different alternative,” Primack told CNBC in an interview in March. “These are tools we’ve been using in our field for a long, long time.”

Last week, Hims said customers can now access compounded GLP-1 medications via a prescription from a licensed health-care provider on the platform. Hims said it plans to make branded GLP-1 medications available to its customers once supply is consistently available. The company’s oral medication kits start at $79 a month, and its compounded GLP-1 injections will start at $199 a month.

Dudum said the company has partnered with one of the largest generic manufacturers in the U.S. and has a certain degree of exclusivity with the facility. The manufacturer has FDA oversight, he said. 

Even before Hims introduced compounded GLP-1 injections to its weight loss offering, the company said it expects the program will generate more than $100 million in revenue by the end of 2025.

Beard, the Ro customer, has had to make some changes since starting the Body Program. She initially took Wegovy with no out-of-pocket costs, thanks to her insurance coverage and a savings card program from Novo Nordisk. But she hit a plateau on the drug, so she switched to Zepbound. 

While there have been some hiccups along the way, Beard says the program has largely been a “seamless” addition to her day-to-day life, and that she no longer thinks about food all the time. She even got a family member to enroll.

“We’re not having any bad side effects, so why go off of it?” she said, adding “it’s helped both of us get to the weight we want.”

Don’t miss these exclusives from CNBC PRO